ClinicalTrials.gg
CompletedNCT02191865Updated Feb 1, 2016Results posted

Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers

A Phase 1 interventional study of Nintedanib and Nintedanib in Hepatic Insufficiency, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-02-01.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Hepatic Insufficiency by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Hepatic Insufficiency · Boehringer Ingelheim.

Enrollment
7th of 13
33 · median 33
Started
2014
the only one that year
Phase 1
12 of 13
none open now
Registered
6th of 13
by date

Among the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim, this one is the 7th largest by enrollment, is the only one that started in 2014, is one of 12 in phase 1, and was the 6th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

None of the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim is open now. The open studies under Hepatic Insufficiency, anywhere →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim as a file.
02

Study summary

The primary objective of this study is to investigate the effect of mild (Child-Pugh A, score 5-6) and moderate (Child-Pugh B, score 7-9) hepatic impairment on the pharmacokinetics, safety and tolerability of nintedanib, in comparison with a control group with normal hepatic function following oral administration of nintedanib as single dose.

03

Conditions studied

  • Hepatic Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy subjects:

  • Male or female subject, healthy according to the investigator's judgement based on a complete medical history, including a physical examination, vital signs (BP, PR), 12-lead , and clinical laboratory
  • Age of 18 to 79 years at screening visit

Hepatically impaired patients as determined by a hepatologist/ gastroenterologist:

  • A documented diagnosis of the impaired hepatic function, determined by hepatologist/gastroenterologist/specialist for internal medicine, must be available in the patient´s source data.
  • Male or female chronic hepatically impaired patient as determined by screening results and classified as A (Child-Pugh score of 5-6 points) or as Child-Pugh B (Child-Pugh score of 7-9 points). Hepatic insufficiency must be diagnosed at least 3 months before screening.
  • Age of 18 to 79 years at screening visit

Exclusion criteria

Exclusion criteria:

Healthy subjects:

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and judged as by the investigator
  • Any laboratory value outside the reference range at screening visit that the investigator considers to be of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders judged as clinically relevant by the investigator
  • Surgery of the gastrointestinal tract that could interfere with kinetics of the trial medication based on the investigator´s judgment
  • Women who are breast feeding or of not using a highly effective method of for at least one month prior to inclusion and at least 3 month after administration of trial medication.

Hepatically impaired patients as determined by a hepatologist/gastroenterologist:

  • Medical disorder, condition or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator or the sponsor
  • Patients with significant diseases other than underlying diagnose of hepatic impairment and concomitant diseases related to it. A significant disease is defined as a disease which in the opinion of the investigator:

    • put the patient at risk because of participation in the study
    • may influence the results of the study
    • is not in a stable condition
  • Surgery of the gastrointestinal tract that could interfere with the kinetics of the trial medication based on the investigator´s judgment
  • Women who are breast feeding or of child-bearing potential not using a highly effective method of birth control for at least one month prior to inclusion and at least 3 month after administration of trial medication
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Mild liver impairment

    Patients with mild hepatic impaired function (Child-Pugh A)

    Drug: Nintedanib

  • Experimental
    Moderate liver impairment

    Patients with moderate hepatic impaired function (Child-Pugh B)

    Drug: Nintedanib

  • Experimental
    Healthy volunteers

    Healthy control subjects

    Drug: Nintedanib

Interventions

06

What researchers measure

Primary outcomes

  1. AUC (0-inf) of Nintedanib

    AUC (0-inf) (Area under the concentration-time curve of the Nintedanib in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: Pre-dose and 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h after drug administration

  2. Cmax of Nintedanib

    Cmax (Maximum measured concentration of the Nintedanib in plasma)

    Time frame: Pre-dose and 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h after drug administration

Secondary outcomes

  1. AUC (0-tz) of Nintedanib

    AUC (0-tz) (Area under the concentration-time curve of the Nintedanib in plasma over the time interval from 0 to the last quantifiable drug plasma concentration)

    Time frame: Pre-dose and 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h after drug administration

  2. Number (%) of Subjects With Drug-related Adverse Events (AEs)

    Number (%) of subjects with drug-related Adverse events (AEs)

    Time frame: (AEs) during the 'on-treatment' period (from administration of trial medication until the end of the 28-day residual effect period); Up to 29 days

07

Results

Posted Feb 1, 2016

Participant flow

Healthy subjects were to be matched to subjects with hepatic impairment ((Child-Pugh A, score 5 or 6),(Child-Pugh B, score 7 to 9)) by age (±10 years), body weight (±10%), sex, race, and smoking habits (current vs. ex- and never smokers).

Participant flow — Overall Study
MilestoneChild Pugh AChild Pugh BHealthy
Started8817
Completed8817
Not completed000

Outcome measures

PrimaryAUC (0-inf) of Nintedanib

AUC (0-inf) (Area under the concentration-time curve of the Nintedanib in plasma over the time interval from 0 extrapolated to infinity)

Time frame:
Pre-dose and 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h after drug administration
Reported as:
Geometric mean · ng*h/mL
AUC (0-inf) of Nintedanib
ng*h/mLChild-Pugh AChild-Pugh BHealthy Matched Child-Pugh AHealthy Matched Child-Pugh B
AUC (0-inf) of Nintedanib200 ± 87.7674 ± 66.392.7 ± 58.577.8 ± 38.2
Statistical analysis
  • Child-Pugh A vs Healthy Matched Child-Pugh A · ANOVA · Ratio of the geometric means: 215.39 · 90% CI 120.71 to 384.32Ratio of Child Pugh A (Test): Healthy Child Pugh A (Reference). The Standard deviation is the Intra-individual gCV
  • Child-Pugh B vs Healthy Matched Child-Pugh B · ANOVA · Ratio of geometric means: 867.13 · 90% CI 572.93 to 1312.41Ratio of Child Pugh B (Test): Healthy Child Pugh B (Reference). The Standard deviation is the Intra-individual gCV
PrimaryCmax of Nintedanib

Cmax (Maximum measured concentration of the Nintedanib in plasma)

Time frame:
Pre-dose and 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h after drug administration
Reported as:
Geometric mean · ng/mL
Cmax of Nintedanib
ng/mLChild-Pugh AChild-Pugh BHealthy Matched Child-Pugh AHealthy Matched Child-Pugh B
Cmax of Nintedanib20.5 ± 68.459.4 ± 87.09.25 ± 54.17.81 ± 49.3
Statistical analysis
  • Child-Pugh A vs Healthy Matched Child-Pugh A · ANOVA · Ratio of the geometric means: 221.76 · 90% CI 134.73 to 365.01Ratio of Child Pugh A (Test): Healthy Child Pugh A (Reference). The Standard deviation is the Intra-individual gCV
  • Child-Pugh B vs Healthy Matched Child-Pugh B · ANOVA · Ratio of geometric means: 761.01 · 90% CI 439.01 to 1319.18Ratio of Child Pugh B (Test): Healthy Child Pugh B (Reference). The Standard deviation is the Intra-individual gCV
SecondaryAUC (0-tz) of Nintedanib

AUC (0-tz) (Area under the concentration-time curve of the Nintedanib in plasma over the time interval from 0 to the last quantifiable drug plasma concentration)

Time frame:
Pre-dose and 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h after drug administration
Reported as:
Geometric mean · ng*h/mL
AUC (0-tz) of Nintedanib
ng*h/mLChild-Pugh AChild-Pugh BHealthy Matched Child-Pugh AHealthy Matched Child-Pugh B
AUC (0-tz) of Nintedanib193 ± 89.5652 ± 66.289.2 ± 59.674.8 ± 38.9
Statistical analysis
  • Child-Pugh A vs Healthy Matched Child-Pugh A · ANOVA · Ratio of the geometric means: 216.79 · 90% CI 120.37 to 390.45Ratio of Child Pugh A (Test): Healthy Child Pugh A (Reference). The Standard deviation is the Intra-individual gCV
  • Child-Pugh B vs Healthy Matched Child-Pugh B · ANOVA · Ratio of geometric means: 870.74 · 90% CI 576.36 to 1315.49Ratio of Child Pugh B (Test): Healthy Child Pugh B (Reference). The Standard deviation is the Intra-individual gCV
SecondaryNumber (%) of Subjects With Drug-related Adverse Events (AEs)

Number (%) of subjects with drug-related Adverse events (AEs)

Time frame:
(AEs) during the 'on-treatment' period (from administration of trial medication until the end of the 28-day residual effect period); Up to 29 days
Reported as:
Number · percentage of participants
Number (%) of Subjects With Drug-related Adverse Events (AEs)
percentage of participantsChild-Pugh AChild-Pugh BHealthy
Number (%) of Subjects With Drug-related Adverse Events (AEs)0.037.517.6

Adverse events

Collected over AEs during the 'on-treatment' period (from administration of trial medication until the end of the 28-day residual effect period); up to 29 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Child Pugh A—0/8 (0%)0/8 (0%)
Child Pugh B—0/8 (0%)3/8 (37.5%)
Healthy—0/17 (0%)3/17 (17.6%)
Most frequent other events
Most frequent other events
EventChild Pugh AChild Pugh BHealthy
DiarrhoeaGastrointestinal disorders0/81/80/17
NauseaGastrointestinal disorders0/81/82/17
PruritusSkin and subcutaneous tissue disorders0/81/80/17
Skin irritationSkin and subcutaneous tissue disorders0/81/80/17
VomitingGastrointestinal disorders0/80/81/17
HeadacheNervous system disorders0/80/81/17

Baseline characteristics

Treated set: The treated set (TS) included all subjects who were dispensed study medication and were documented to have taken atleast one dose of investigational treatment.

Age, Continuous
Age, Continuous(years)Child Pugh AChild Pugh BHealthyTotal
Mean60.6 ± 8.156.6 ± 6.557.6 ± 8.458.1 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Child Pugh AChild Pugh BHealthyTotal
Female33713
Male551020
08

Study locations

1 site
  • 1199.200.49001 Boehringer Ingelheim Investigational Site
    Kiel, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Dec 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2014
First posted
Jul 16, 2014
Start
Jul 2014
Primary completionActual
Dec 2014
CompletionActual
Jan 2015
Results first posted
Feb 1, 2016
Last update
Feb 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02191865
Responsible party
Sponsor
First posted
Jul 16, 2014
Start date
Jul 2014
Primary completion
Dec 2014
Completion
Jan 2015
Results posted
Feb 1, 2016
Last update
Feb 1, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion